Findings

What do systematic reviews say?

12 questions · 12 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 16.7%GRADE not reported 2 · 16.7%Very low 1 · 8.3%Low 5 · 41.7%Moderate 2 · 16.7%High 0 · 0%

Dihydropyridine calcium channel blockers vs placebo or control

Predialysis systolic blood pressure · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Dihydropyridine calcium channel blockers vs other antihypertensives

Other side effects · people with CKD requiring dialysis

The review found no eligible studies for this question.

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dihydropyridine calcium channel blockers vs placebo or control

Diastolic blood pressure · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Low

Dihydropyridine calcium channel blockers vs placebo or control

Cardiovascular mortality · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 124 participants
GRADE not reported

Dihydropyridine calcium channel blockers vs placebo or control

Intradialytic hypotension · people with CKD requiring dialysis

Dihydropyridine calcium channel blockers showed no clear difference in intradialytic hypotension compared with placebo/control (low certainty).

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
RR 0.54 [0.25, 1.15]
2 studies · 287 participants
Low

Dihydropyridine calcium channel blockers vs placebo or control

Other side effects · people with CKD requiring dialysis

The review found no eligible studies for this question.

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dihydropyridine calcium channel blockers vs other antihypertensives

Predialysis systolic blood pressure · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 180 participants
Low

Dihydropyridine calcium channel blockers vs other antihypertensives

Diastolic blood pressure · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 180 participants
Low

Dihydropyridine calcium channel blockers vs other antihypertensives

Cardiovascular mortality · people with CKD requiring dialysis

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 164 participants
GRADE not reported

Dihydropyridine calcium channel blockers vs other antihypertensives

Intradialytic hypotension · people with CKD requiring dialysis

It is very uncertain whether dihydropyridine calcium channel blockers changes intradialytic hypotension compared with other antihypertensives (very low certainty).

1 finding from 1 review

Calcium channel blockers for people with chronic kidney disease requiring dialysis 2020 · Cochrane Headline outcomes only
RR 2.88 [0.12, 68.79]
1 study · 92 participants
Very low

Dihydropyridine calcium channel blockers vs placebo

Variation in the decrease in 24‐hour ambulatory hourly SBP (at 3 to 12 weeks) · adults with primary hypertension

1 finding from 1 review

Time course for blood pressure lowering of dihydropyridine calcium channel blockers 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2768 participants
Moderate

Dihydropyridine calcium channel blockers vs placebo

Variation in the decrease in 24‐hour ambulatory hourly DBP (at 3 to 12 weeks) · adults with primary hypertension

1 finding from 1 review

Time course for blood pressure lowering of dihydropyridine calcium channel blockers 2014 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 2768 participants
Moderate